Press Releases

Filter by Category

All Annual Meetings Blog Events Newsletters Podcasts Posters Publications Webinars Workshops

Filter by Program

Filter by Date

July 21, 2020

C-Path’s PSTC, D-RSC Receive Positive FDA Response to Plan for Liver Safety Biomarker

Biomarker aims to provide an additional tool for detecting the onset of hepatic injury in clinical trials involving patients with

July 14, 2020

C-Path Data Collaboration Center Analytics Team Wins Metadata Automation DREAM Challenge

TUCSON, Ariz., July 14, 2020 — Tucson-based Critical Path Institute (C-Path) today proudly announced that the analytics team f

June 23, 2020

C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19

Clinicians to report novel uses of existing drugs through FDA-NCATS CURE ID Mobile App. TUCSON, Ariz., June 23, 2020 — As millio

June 20, 2020

C-Path’s Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint

Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplan

May 13, 2020

C-Path and Provention Bio Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes

TUCSON, Ariz., and OLDWICK, N.J. May 13, 2020 — The Critical Path Institute (C-Path) and Provention Bio, Inc. (Nas

April 30, 2020

C-Path Appoints Two New Members to Board of Directors

TUCSON, Ariz., April 30, 2020 — Tucson-based Critical Path Institute (C-Path) today announced the appointment of two new

April 29, 2020

C-Path ePRO Consortium and PRO Consortium Announce COVID-19 Risk Assessment and Mitigation Strategies

Recommendations provided for sponsors and eCOA providers to facilitate the continued collection of PRO data in clinical trials. &n

April 28, 2020

C-Path Receives Letter of Support from EMA on Type 1 Diabetes Biomarker Initiative

TUCSON, Ariz., April 28, 2020 — The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D

April 21, 2020

C-Path Awarded FDA Contract to Enhance the Assessment of Clinical Outcomes in Pediatric Asthma Treatment Trials

Resulting novel drug development tools will support patient-focused drug development for children with asthma TUCSON

March 19, 2020

C-Path Receives FDA Grant to Establish Rare Disease Clinical Outcome Assessment Consortium

TUCSON, Ariz., March 19, 2020 — The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Res

Previous2324 25...34 Next